RhoA is a member of the Rho family small GTPases that are implicated in various cell functions including proliferation and survival. However, the physiological role of RhoA in vivo remains largely unknown. Here, we deleted RhoA in the B cell and hematopoietic stem cell (HSC) populations in RhoA flox/flox mice with CD19 and Mx promoter-driven Cre expression, respectively. Deletion of RhoA by CD19
Introduction
B lymphocytes differentiate from bone marrow hematopoietic stem cells (HSCs) through a series of developmental stages [1] [2] [3] [4] . In the first stage, B cell progenitors, or proB cells, undergo immunoglobulin heavy chain gene rearrangement to differentiate into preB cells. PreB cells then undergo immunoglobulin light chain gene rearrangement to further develop into immature B cells. Immature B cells emigrate from the bone marrow to the spleen, where they become transitional (T) B cells. Although a small proportion of T B cells mature into non-circulating marginal zone (MZ) B cells, most differentiate into follicular (FO) B cells that circulate to spleen follicles, lymph nodes, and bone marrow.
RhoA is an intracellular signal transducer of the Rho family small GTPases that cycles between an inactive GDP-bound form and an active GTP-bound form under tight regulation [5, 6] . Activated RhoA binds to a variety of effector molecules (e.g. ROCK and mDia) to modulate actin cytoskeleton organization, adhesion, migration, proliferation, and survival in mammalian cells [7] [8] [9] [10] [11] . In B cells, RhoA transduces signals from the B cell receptor (BCR) to regulate phosphatidylinositol-4, 5-bisphosphate synthesis, PLCc2 activation, calcium influx, protein kinase D activation, and B cell proliferation [12, 13] . RhoA also plays a role in CCL19-and CCL21-induced migration of B-chronic lymphocytic leukemia cells [14] . However, the role of RhoA in B cell development remains unknown, although three closely related members of Rho GTPases, Rac1, Rac2, and Cdc42 are all required for B cell differentiation [15, 16] . The majority of published literatures for RhoA have employed overexpression of constitutively active or dominant negative RhoA mutants. While this strategy has resulted in a number of key discoveries, including the critical role of RhoA in actin stress fiber formation and cell adhesion [7] , it is compromised by the promiscuous nature of these RhoA mutants [17] [18] [19] [20] . For instance, RhoA dominant negative mutants sequester upstream guanine nucleotide exchange factors (GEFs) that are capable of activating additional Rho GTPases, potentially leading to non-specific phenotypes. In addition, overexpression of constitutively active GTP-bound RhoA mutants might activate a number of effectors (e.g., ROCK) shared between RhoA and other Rho GTPases, potentially causing off-target effects. Finally, a strictly balanced RhoA GTP-binding/GTPhydrolysis cycle is required for proper signaling. As such, the overexpression of these mutants might introduce artifacts by locking RhoA into a single conformation at a fixed intracellular location. It is therefore highly desirable to use a gene targeting strategy to assess the physiological functions of RhoA.
Several studies have reported the use of RhoA conditional gene targeting to define RhoA functions in mice [21] [22] [23] . Deletion of RhoA in skin cells revealed that, while RhoA is not required for skin development, it is indispensible for the contraction and directed migration of primary keratinocytes. In the nervous system, RhoA maintains adherens junctions and modulates neuronal cell proliferation. Furthermore, contrary to the conventional view that RhoA is essential for actin cytoskeleton rearrangement and cell adhesion, RhoA-deficient primary mouse embryonic fibroblasts (MEFs) display normal actin stress fiber and focal adhesion complex formation. Nonetheless, RhoA is critical for MEF cell proliferation.
To assess the physiological role of RhoA in B cell development, we generated mouse strains deficient for RhoA expression in either B cells or HSCs by crossing RhoA flox/flox mice with CD19 Cre/+ or Mx-Cre transgenic mice. Using these targeted deletion models, we demonstrate that RhoA is crucial for B cell development and for B cell activating factor (BAFF)-mediated B cell survival, but not for BCR-mediated proliferation and survival.
Results

Generation of RhoA-deficient B cells by CD19
Cre/+ To study the role of RhoA in B cell development, RhoA flox/flox mice [22, 23] were crossbred with CD19
Cre/+ transgenic mice to generate CD19
Cre/+ ; RhoA flox/flox (RhoA 2/2 ) mice (Fig. 1A) . Because CD19
Cre/+ transgenic mice are generated by inserting the Cre gene into the CD19 locus, the transgenic mice are depleted of one copy of the CD19 gene, which may affect B cell development [24] . We thus used CD19
Cre/+ ; RhoA +/+ mice, but not RhoA flox/flox mice, as control for RhoA 2/2 mice. B220 + B cells were purified from the bone marrow and spleen of RhoA 2/2 and control mice. Western blot analysis indicated that RhoA expression was dramatically reduced in splenic B cells, but less so in bone marrow B cells in the mutant mice (Fig. 1A) . (Fig. 1C) . In agreement, hematoxylin and eosin staining of RhoA 2/2 spleen sections revealed lymphoid hypoplasia and loss of follicular architecture (Fig. 1D) . Moreover, B cells were decreased in the lymph nodes and blood in the absence of RhoA (data not shown). Taken together, these results suggest that RhoA is critical for the late B cell development.
Effects of RhoA deletion on B cell development
Effects of RhoA deletion on B cell proliferation and survival
Cell proliferation is crucial for B cell development [4] . To explore the mechanisms underlying impaired splenic B cell development in RhoA-deficient mice, we determined the proliferative capacity of RhoA 2/2 splenic B cells upon in vitro culture with either LPS or anti-IgM F(ab') 2 antibody to crosslink BCR. Surprisingly, we found that under either condition the RhoA 2/2 B cell proliferation profile did not statistically differ from control cells ( Fig. 2A) . These results suggest that RhoA is dispensable for Tolllike receptor-or BCR-mediated B cell proliferation. Along with recent studies showing that RhoA-deficient neural progenitor cells are hyperproliferative while RhoA-deficient MEFs have impaired proliferation [22, 23] , it appears that RhoA plays cell type-specific roles in the regulation of cell proliferation.
B cell survival constitutes another important requirement for B cell development [2] . Since RhoA reportedly regulates cell survival [6] , we examined the survival index of RhoA-deficient B cells by Annexin V staining and found that Ex vivo splenic B cells from RhoA 2/2 mice had no detectable survival defect (Fig. 2B ). Moreover, control and RhoA2/2 B cells cultured in vitro with anti-IgM F(ab') 2 antibody exhibited a similar increase in survival induced by BCR ligation (Fig. 2C) . However, RhoA 2/2 B cells were resistant to B cell survival factor BAFF-mediated apoptosis inhibition while control B cells were rescued from apoptosis by BAFF in a dose-dependent manner (Fig. 2C) . Interestingly, treatment with Y27632, a chemical inhibitor of the RhoA downstream effector ROCK, partially blunted the survival response of control B cells to BAFF (Fig. 2C ), suggesting that RhoA modulates BAFF-mediated B cell survival, at least in part, through activation of ROCK. The lack of a survival response of RhoA 2/2 B cells to BAFF correlates with a reduction of BAFF receptor (BAFFR) on T, FO, and MZ B cells, as demonstrated by a reduction of BAFFR + cells and the mean fluorescence intensity per cell (Fig. 2D) . The reduction of cell surface BAFFR is not likely due to a trafficking defect since Western blot revealed that RhoA 2/2 B cells had a 50% reduction in BAFFR protein expression compared to control B cells (Fig. 2E ). Quantitative real-time PCR analysis demonstrated a reduction of BAFFR mRNA in RhoA 2/2 B cells, suggesting that the reduction in BAFFR protein is due to reduced transcription and not a reduction in protein stability (Fig. 2F) . Indeed, RhoA deficiency completely abolished BAFF-mediated Akt activation, likely due to decreased BAFFR expression (Fig. 2G) . In contrast to BAFFR, RhoA deficiency had no effect on BCR expression as revealed by comparable levels of IgM in control and RhoA 2/2 B cells (Fig. 2E ), in agreement with the normal proliferative or survival response of RhoA 2/2 B cells to BCR ligation. Collectively, these results suggest that RhoA selectively regulates BAFF-mediated B cell survival by controlling BAFFR expression.
Effects of HSC deletion of RhoA on B cell precursor development in bone marrow
As previously demonstrated, CD19
Cre/+ -mediated RhoA deletion in bone marrow B cells is inefficient (Fig. 1A) , precluding further examination of the role of RhoA in their development. Instead, we employed an alternatively method to generate RhoA 2/2 HSCs by crossing RhoA flox/flox with Mx-Cre transgenic mice and inducing Cre expression in Mx-Cre; RhoA flox/flox mice with polyI:C (Fig. 3A) . RhoA flox/flox littermates were used as control and also treated with polyI:C. Since Mx-Cre; RhoA flox/flox mice die within eight days after polyI:C induction, we analyzed the mice at day six and found that RhoA was almost completely absent from the bone marrow (Fig. 3A) . FACS analysis indicated that both the percentage and number of common lymphoid progenitors (CLP) were elevated in Mx-Cre; RhoA flox/flox mice (Fig. 3B ), but the proB/preB and immature B cell subsets were markedly decreased (Fig. 3C) . The percentage, but not number, of recirculating mature B cells in bone marrow was increased in Mx-Cre; RhoA flox/flox mice ( Fig. 3C and data not shown), likely due to a compensatory effect of the decreased proB/preB and immature B cells. These results suggest that RhoA deficiency inhibits bone marrow B cell development at the CLP differentiation stage. Thus, RhoA also plays a critical role in early B cell development.
Discussion
In [15, 16] . In contrast, RhoA deficiency has no effect on BCR-mediated cell proliferation, whereas ablation of either Cdc42, Rac2 or both Rac1 and Rac2 dampens BCR signaling and cell proliferation [15, 16, 25] . Moreover, deletion of Rac2 or both Rac1 and Rac2, but not Cdc42, compromises B cell migration [16, 25, 26] , which is thought to play a role in B cell development [27] . It remains to be determined whether depletion of RhoA affects B cell migration. These data combined with our findings suggest that different aspects of B cell development may require distinct Rho GTPases.
The lack of response of RhoA 2/2 B cells to BCR-mediated cell proliferation might be due to functional redundancy of other Rho GTPase family members, including Cdc42, Rac1, and Rac2, or compensatory activation of RhoB and/or RhoC [15, 16, 25] . We could not detect an effect of RhoA deficiency on bone marrow B cell development, potentially due to the poor deletion efficiency of CD19 Cre/+ in these cells. Indeed, CD19 Cre/+ is reportedly less efficient in deleting polb in preB cells than in splenic B cells [28] . Furthermore, we have observed that CD19
Cre/+ only partially deletes Cdc42 in proB/preB cells [16] . As such we speculate that the residual RhoA expression in RhoA 2/2 bone marrow B cells is attributable to the incomplete deletion of RhoA in proB/preB cells. So to study the role of RhoA in bone marrow B cell development, we instead used Mx-Cre to remove RhoA from HSCs. Noting that Mx-Cre; RhoA flox/flox mice die within eight days after polyI:C injection, likely due to severe anemia, we analyzed ; RhoA f lox/f lox mouse models has allowed us to investigate specific roles for RhoA in both early bone marrow and late splenic B cell development.
The survival of peripheral B cells is regulated by BCR and BAFFR [29] . Interestingly, we find that RhoA selectively regulates BAFF/BAFFR-but not BCR-mediated survival. Hence, RhoA appears to play a stimulus-specific role in B cell survival. This concept is supported by a number of observations in other cell types. For instance, RhoA is important for thrombin-induced ICAM-1 expression, but not for the induction of ICAM-1 expression by TNFa, in endothelial cells [30] . In chondrocytes, RhoA regulates TGF-b-but not IL-1-induced actin cytoskeleton reorganization [31] . Furthermore, RhoA mediates TNFa-but not UV-induced NF-kB activation in COS-7 cells [32] .
Since BAFFR expression is reduced in RhoA 2/2 splenic B cells, RhoA may regulate BAFF/BAFFR-mediated B cell survival by modulating BAFFR expression. In addition to its primary functions in regulating BAFF-induced B cell survival, homeostasis and differentiation [29, [33] [34] [35] [36] , BAFFR has also been shown to regulate the production of naturally occurring IgM, IgG1 and T cell-dependent IgG and to be involved in T-cell independent class switch to IgG and IgE [35, 36] . It is therefore plausible that RhoA might play a role in antibody formation. BAFFR has recently been shown to regulate B cell chemotaxis [37] . It is conceivable then that RhoA contributes to B cell chemotaxis via regulation of BAFFR expression. Finally, literature indicates that BAFFR is required for CD21 and CD23 expression [36] , so RhoA could regulate the differentiation of FO and MZ B cells by affecting BAFFR-mediated expression of FO and MZ B cell surface markers.
Materials and Methods
Ethics statement
This study involved the use of mice and was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Cincinnati Children's Hospital Research Foundation. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Cincinnati Children's Hospital Research Foundation (permit Number: 8D06052). Mice were anesthetized using ketamine (80-100 mg/ kg IM), aceptromazine (4-6 mg/kg IM) and atropine (0.1 mg/kg IM) and anesthesia was maintained using ketamine (30 
Mouse gene targeting
Conditionally targeted RhoA flox/flox mice were generated as previously described [22, 23] . The floxed allele contains loxP sites flanking exon 3 of the RhoA allele (allele symbol: Rhoa tm1Yuyo [22] ). To delete RhoA in vivo in the B cell lineage, RhoA flox/flox mice were mated with mice expressing Cre recombinase under the control of a CD19 proximal promoter (allele symbol: CD19 tm1(cre)Cgn [24] ) (Jackson Laboratory). Mice used for experiments ranged in age from six to twelve weeks. To delete RhoA in vivo in HSCs, Mx-Cre; RhoA flox/flox mice were generated by breeding Immunoblotting B cells were purified from bone marrow and spleen using B220 Microbeads (Miltenyi Biotec). Total bone marrow cells and purified B cells were lysed and protein content was normalized by Bradford assay. Lysates were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis. Western blot was performed using the following antibodies: RhoA (67B9), phospho-Akt (D9E), and Akt (C67E7) (Cell Signaling Technology), IgM (m chain specific) (Jackson ImmunoResearch Laboratories), and BAFFR (G-20) (Santa Cruz).
Characterization of B cell development by cell surface staining
Single cell suspensions were prepared from bone marrow and spleen. Cells were incubated with various combinations of the following antibodies at room temperature for 20 minutes: B220 (RA3-6B2), CD21 (7G6), CD23 (B3B4), CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7), Gr1 (RB6-8C5), CD11b (M1/70), TER119 (TER-119), c-kit (2B8), and Sca1 (D7) (BD Biosciences) and IL7Ra (A7R34) and BAFFR (eBio7H22-E16) (eBioscience).
Flow cytometry analysis was performed on a FACSCanto system using FACSDiVa software (BD Biosciences).
Cell apoptosis analysis
B cells were purified from spleen using B220 microbeads. The cells were cultured for 72 hours on 96-well plates at a density of 10 6 cells/mL in 200 mL of B cell culture medium (10% fetal calf serum; 10 mM Hepes pH 7.3; L-glutamine; Penicillin/Streptomycin; non-essential amino acids; sodium pyruvate; and 5610
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M 2-mercaptoethanol, in RPMI-1640) in the presence or absence of 2 mg/mL of anti-IgM F(ab') 2 antibody (Jackson Immunoresearch Laboratories), or various concentrations of recombinant human BAFF (PeproTech). The cultured B cells and ex vivo B cells were then stained with Annexin V (BD Biosciences) followed by flow cytometry analysis.
Cell proliferation assay
Purified splenic B cells were cultured for 48 hours on 96-well plates at 2610 6 cells/mL in 200 mL of B cell culture medium in the presence or absence of 2 mg/mL of either anti-IgM F(ab') 2 antibody or LPS. Cell growth rate was analyzed by using the CellTiter 96H AQ ueous Non-Radioactive Cell Proliferation Assay (MTS) kit (Promega).
Hematoxylin and eosin staining
Spleens were fixed in 10% buffered formalin, embedded in paraffin, sectioned at 5 mM and stained with hematoxylin and eosin.
Gene expression analysis
RNA was isolated from splenic B cells using RNeasy Micro Kit (QIAGEN) and converted to cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems Inc). Real-time polymerase chain reaction (PCR) was performed with a Taqman system on a 7900HT Real-Time machine (Applied Biosystems Inc). The primer sequences for amplification of BAFFR cDNA were CCTCCGCTCAAAGAAGATGCA (forward primer) and GTGGAGCCCAGTTCTGT (reverse primer). Data were analyzed using SDS 2.3 software (Applied Biosystems Inc) and normalized to glyceraldehyde-3-phosphate dehydrogenase.
Statistical Analysis
Data are expressed as the mean 6 standard deviation (SD). Data were analyzed by a Student's unpaired t-test with a twotailed distribution. Significance was accepted at p,0.05.
